Citi downgraded Illumina (ILMN) to Sell from Neutral with a price target of $80, down from $85. The firm sees “significant” risk to estimates in the second half of 2025 and 2026 for Illumina. Citi cites funding uncertainty and increasing competitive risk for the downgrade to Sell.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ILMN:
- Illumina’s Strategic Acquisition of SomaLogic: Enhancing Proteomics Offerings and Long-term Financial Growth
- NIH directs staff not to end any extra research projects for now, NY Times says
- Cathie Wood’s ARK Investment buys 28K shares of Illumina today
- Illumina’s Strategic Acquisition of SomaLogic: Hold Rating Reaffirmed Amidst Unchanged Financial Outlook
- Cautious Hold Rating on Illumina Amid Uncertain Financial Impact of SomaLogic Acquisition